Article thumbnail

A Lipoprotein Lipase–Promoting Agent, NO-1886, Improves Glucose and Lipid Metabolism in High Fat, High Sucrose–Fed New Zealand White Rabbits

By Weidong Yin, Zhonghua Yuan, Kazuhiko Tsutsumi, Yuxiang Xie, Qiuju Zhang, Zongbao Wang, Guoxiang fu, Guang Long and Yongzong Yang


The synthetic compound NO-1886 is a lipoprotein lipase activator that lowers plasma triglycerides and elevates high-density lipoprotein cholesterol (HDL-C). Recently, the authors found that NO-1886 also had an action of reducing plasma glucose in high-fat/high-sucrose diet–induced diabetic rabbits. In the current study, we investigated the effects of NO-1886 on insulin resistance and β-cell function in rabbits. Our results showed that high-fat/high-sucrose feeding increased plasma triglyceride, free fatty acid (FFA), and glucose levels and decreased HDL-C level. This diet also induced insulin resistance and impairment of acute insulin response to glucose loading. Supplementing 1% NO-1886 into the high-fat/high-sucrose diet resulted in decreased plasma triglyceride, FFA, and glucose levels and increased HDL-C level. The authors also found a clear increased glucose clearance and a protected acute insulin response to intravenous glucose loading by NO-1886 supplementation. These data suggest that NO-1886 suppresses the elevation of blood glucose in rabbits induced by feeding a high-fat/high-sucrose diet, probably through controlling lipid metabolism and improving insulin resistance

Topics: Research Article
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2002). A diet high in saturated fat and sucrose alters glucoregulation, and induces aortic fatty streaks in New Zealand White rabbits.
  2. (1997). Antiatherogenic effects of a novel lipoprotein lipase-enhancing agent in cholesterol-fed New Zealand White rabbits.
  3. (2000). Comparison of the effects of sucrose and fructose on insulin action and glucose tolerance.
  4. (1995). Correction of hypertriglyceridemiawithlowhigh-densitylipoproteincholesterol by the novel compound NO-1886, a lipoprotein lipasepromoting agent, in STZ-induced diabetic rats.
  5. (1996). Diabetic dyslipidemia: Basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes,
  6. (2002). Diabetic dyslipidemia.
  7. (2000). Effects of NO1886, a lipoprotein lipase promoting agent on homozygous and heterozygous WHHL rabbits.
  8. Gradual loss of pancreatic beta-cell insulin, glucokinase and GLUT2glucosetransporterimmunoreactivitiesduringthetime course of nutritionally induced type-2 diabetes in Psammomys obesus (sand rat).
  9. Hara,T.,Kusunoki,M.,Tsutsumi,K.,etal.(1998)Alipoprotein lipase activator, NO-1886, improves endothelium-dependent relaxationofrataortaassociatedwithaging.Eur.J.Pharmacol.,
  10. Kusunoki,M.,Hara,T.,Tsutsumi,K.,etal.(2000)Thelipoproteinlipaseactivator,NO-1886,suppressesfataccumulationand insulin resistance in rats fed a high-fat diet.
  11. (2001). Lipotoxicity and glucotoxicity in type 2 diabetes. Effects on development and progression.
  12. (1999). Mechanisms for hyperglycemia in the metabolic syndrome: The key role of ¯-cell dysfunction.
  13. (2001). Pathogenesis of dyslipidemia
  14. (2000). Pathogenesis of type 2 diabetes: The relative contribution of insulin resistance and impaired insulin secretion.
  15. (1998). The action of novel lipoprotein lipase activator, NO-1886, in hypertriglyceridemic fructose-fed rats.
  16. (1993). The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-termadministrationinhibitsatherogenesisinthecoronary arteries of rats with experimental atherosclerosis.
  17. (1998). Treatment of diabetic dyslipidemia.
  18. Yin,W.,Tsutsumi,K.,Yuan,Z.,andYang,B.(2002)Alipoprotein lipase activator NO-1886 suppresses atherosclerosis in aorta of mild diabetic rabbits.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.